

UTAH MEDICAL BOARD MEETING MINUTES

JUNE 18, 2026
SALT LAKE CITY, UT 84114

CONVENED: 9:00 A.M.

ADJOURNED: 11:05 A.M.

DIVISION STAFF PRESENT:

Division Director: Mark Steinagel
Licensing Administrator: Larry Marx
Legal Analyst: Lauren Harvey
Compliance Specialist: Tori Sackett

Assistant Division Director: Deborah Blackburn
Board Administrator: Allison Pulsipher
Pharmacy Specialist: Maddy Holt

BOARD MEMBERS PRESENT:

Dr. Alan Smith, MD, Chair
Dr. Craig Davis, MD, Vice-Chair
Dr. William Hamilton, MD
Dr. Stephen Voss, MD
Dr. Spencer Pierson, MD

Dr. Jonathan Olsen, DO
Shaun Curran, PA-C
James Sutton, PA-C
Marie Pittman-Cherrington, PA-C
Grant Madsen, Public Member

BOARD MEMBERS NOT PRESENT:

Dr. Susan Wiet, MD
Dr. Greg Hobson, DO

Dr. Nicole Clark, MD
Rachel MacKay, Public Member

GUESTS:

Adam Brickman
Alice Schwarze, Office of AI Policy
Cam Bronson, Office of AI Policy
Courtney Rae, Office of AI Policy
Emma Beavis
Frank Meyers, FSMB
Grace Wingate, Office of AI Policy
Karissa Gardner, Department of Commerce
Ken Whitmore, Surescripts LLC
Keri Jensen, Office of AI Policy
Kevin Bhnenblust, WY Board of Medicine
Mario Aguilar

Dr. Mark Sendak, Health AI
Mark Staz, FSMB
Marla Kanemitsu
Melanie Hall, Department of Commerce
Michelle McOmber, UMA
Nikhil Jaiswal, McGill University
Ramsey Zengbean
Thomas Sandholm
Dr. Tina Hernandez-Boussard, Stanford University
Victoria Tiase, University of Utah
Zach Boyd, Office of AI Policy

Note: Other guests may have been in attendance electronically but were not identified.

ADMINISTRATIVE BUSINESS:

CALL MEETING TO ORDER

Dr. Smith called the meeting to order at 9:00 am.

DISCUSSION ITEMS:

AI Usage in Medicine

Context and Summary - Zach Boyd (Audio – 0:11:38)

Mr. Boyd provided the Board with an overview of the AI Office early pilot programs and updates they have made.

Mr. Boyd reviewed the long-term regulatory model ideas, the risks they have identified, and projected benefits.

Utah's AI Landscape – Dr. Jonathan Olsen (Audio – 0:21:52)

Dr. Olsen highlighted the regulatory concerns with the Board.

Dr. Olsen recommended the Board think about proposing a work group or other review recommendations for the Office of AI Policy.

Expert Comment (Audio – 0:28:30)

Dr. Olsen introduced the FSMB Representatives to the Board.

Mr. Staz informed the Board FSMB has been following Utah's sandbox process and pilot programs closely.

Mr. Staz informed the Board FSMB's regulatory guidance has been for AI to be used as a tool to assist the provider and they have not created regulatory for AI to be used autonomously.

Mr. Meyers informed the Board of the 2024 FSMB announcement and policy for use of AI in medicine.

Mr. Meyers informed the Board of the discussions they have been having with different groups, hospitals, and clinicians.

Dr. Olsen introduced the academic groups invited to the Board.

Dr. Mark Sendak introduced himself and provided the Board with recommendations to move forward safely with the integration of AI in medicine.

Dr. Sendak reminded the Board of the importance of transparency when evaluating the integration of AI in medicine.

Dr. Tina Hernandez-Boussard informed the Board of the different groups she has been working with to regulate AI in Medicine and the importance of remembering this is bigger than just a state project.

Mr. Nikhil Jaiswal informed the Board of the research group he works with at MIT.

Mr. Jaiswal stated the AI tools should be regulated not only on their current product, but also on their possible output.

Dr. Olsen asked if Ms. McOmber, UMA, would like to provide comment.

Ms. Michelle McOmber informed the Board of the discussions being had by the UMA.

Ms. McOmber stated the UMA does not believe AI should replace care and proposed many questions that everyone should be addressing when developing systems and integrating AI into medicine.

Board Discussion (Audio – 1:12:25)

Dr. Hamilton informed the Board he has been discussing this topic with many other providers to gather input from the profession.

Dr. Voss asked Dr. Sendak how he would propose incentivizing clinicians to spend the time evaluating the possible successes and failures with the usage of AI in their medical care.

Dr. Sendak informed the Board how to address these issues and states the sandbox model helps provide regulatory balance on these issues.

Mr. Madsen informed the Board of his insight on the discussions had today and feels there is a great framework for moving forward.

Dr. Hamilton reminded the Board of the importance of liability and accountability moving forward.

Dr. Olsen and Dr. Smith asked if the Board had opinions regarding how to move forward; if the Board should be creating a workgroup or a different review panel.

Mr. Curran stated the Office of AI Policy may want to work with the local universities and institutions to closely monitor the integration of these models into medicine.

Ms. McOmber stated there should be some guidelines regarding what AI can currently do in medicine, then slowly integrate it into other areas.

Dr. Sendak the best way to address these problems and concerns is to have the front-line clinicians work within the landscape themselves.

Dr. Smith asked Mr. Boyd for his comments regarding today's discussion.

Mr. Boyd informed the Board what his office is hoping to focus on and their network access.

Mr. Sutton reminded the Board of their duty to protect the safety of the public and that focus originally started as "how do we do this" rather than "should we do this".

Dr. Smith asked Mr. Boyd and the Department if the Board had the authority to propose a working group or peer review committee with the Office of AI Policy.

Mr. Steinagel informed the Board of their options moving forward.

Mr. Marx asked for names of those interested in working with the Office of AI Policy.

Dr. Smith asked if this workgroup should extend beyond just the Medical Board or if it should be a sub-group under the Medical Board.

Mr. Boyd provided the Board with a few suggestions.

Mr. Meyers informed the Board FSMB is hoping to provide guidelines within their workgroups to help Utah and other states create their framework for moving forward.


2026 MEETING SCHEDULE:

JULY 16TH, SEPTEMBER 17TH, NOVEMBER 19TH

ADJOURN:

Meeting adjourned at 11:05 A.M.

Note: These minutes are not intended to be a verbatim transcript but are intended to record the significant features of the business conducted in this meeting. Discussed items are not necessarily shown in the chronological order they occurred.

7-16-26 (ss) 
Date Approved **Chairperson, Utah Medical Licensing Board**

7/16/2026 (ss) 
Date Approved **Licensing Administrator, DOPL**